Lupus nephritis
Conditions
Interventions
Belimumab Group:NA
Telitacicept Group:NA
Sponsors
Shandong Provincial Qianfoshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 65 years old; 2.Compliant with the revised SLE classification criteria of the American College of Rheumatology in 1997 or the SLE diagnostic classification criteria published by EULAR/ACR in 2019; 3.Urine protein quantification >=1g/d, or urine PCR>=1g/g, or qualitative urine protein test in urine routine >=1+; 4.Patients who have used telitacicept or belimumab for at least 12 weeks.
Exclusion criteria
Exclusion criteria: 1.Having active central nervous system diseases; 2.eGFR less than 30 mL/min/1.73m^2, or undergoing hemodialysis or having a kidney transplant; 3.Pregnant women, those planning to become pregnant in the near future, and lactating women; 4.Research participants who also take part in other clinical studies; 5.Less than 12 weeks of treatment with telitacicept or belimumab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of effective treatment for major kidney diseases; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete renal response rate; | — |
Countries
China
Contacts
Public ContactYipeng Liu
The First Affiliated Hospital of Shandong First Medical University(Shandong Provincial Qianfoshan Hospital)
Outcome results
None listed